Clinical trial · Observational
Ipilimumab 12-month Intensive Pharmacovigilance Protocol
NCT02050594CI-TRIAL-00018469completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of the protocol is to identify and describe observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela during the study period
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ipilimumab | Drug | Ipilimumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Melanoma patients on Ipilimumab
- description
- All unresectable, recurrent or metastatic melanoma patients
- interventionNames
- Drug: Ipilimumab
Primary outcomes (1)
- measure
- Descriptive statistics of observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela
- timeFrame
- Up to 12 months of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Age of 18 years or older on date of first dose of Ipilimumab * Subjects who received at least 1 dose of Ipilimumab for the treatment of unresectable, recurrent or metastatic melanoma in Venezuela Exclusion Criteria: * Subjects who received Ipilimumab as part of a clinical trial * Subjects who received Ipilimumab for any indication other than local approval (ie, unresectable or metastatic melanoma)
References
Publications (0)
Data not yet available
No reference posted for this study.